Pharma · Private company
Grifols Therapeutics LLC
Track this companyFree. Adds Grifols Therapeutics LLC to your Dealase workspace and tells you when its record changes.
Clinical trials244 recruiting or active
Pipeline programs31From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline31
- 0.9% Sodium Chloride for Injection, USPPhase 3 · Pulmonary Emphysema in Alpha-1 PI DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- Albutein 20%Phase 3 · Decompensated Cirrhosis and AscitesClinicalTrials.gov · fetched Nov 12, 2026
- Alpha-1 15%Phase 3 · Alpha 1 Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- Alpha-1 MPPhase 3 · Pulmonary Emphysema in Alpha-1 Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- Alpha-1 MPPhase 3 · Pulmonary Emphysema in Alpha-1 PI DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- Gamunex-CPhase 3 · CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)ClinicalTrials.gov · fetched Nov 12, 2026
- Gamunex-CPhase 3 · Primary ImmunodeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- IGIV-C 10%Phase 3 · Primary ImmunodeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- IGSC 20%Phase 3 · Primary ImmunodeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- IGSC 20% 150 mg/kgPhase 3 · Primary ImmunodeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- IGSC 20% daily push versus 2 times per week pumpPhase 3 · Primary ImmunodeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- IGSC 20% daily push versus every 2 weeks pumpPhase 3 · Primary ImmunodeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- IGSC 20% daily push versus once a week pumpPhase 3 · Primary ImmunodeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- IVIG-PEGPhase 3 · Primary ImmunodeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- Liquid Alpha1-PIPhase 3 · Alpha 1 Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- SMTPhase 3 · Decompensated Cirrhosis and AscitesClinicalTrials.gov · fetched Nov 12, 2026
- XembifyPhase 3 · HypogammaglobulinemiaClinicalTrials.gov · fetched Nov 12, 2026
- XembifyPhase 3 · CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)ClinicalTrials.gov · fetched Nov 12, 2026
- Albutein 5%Phase 2 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Alpha-1 15%Phase 2 · Alpha1-Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- AlphanatePhase 2 · Hemophilia A, CongenitalClinicalTrials.gov · fetched Nov 12, 2026
- AT-III (Human)Phase 2 · Cardiac SurgeryClinicalTrials.gov · fetched Nov 12, 2026
- GAMUNEX-CPhase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- Human Plasma-Derived Fibrinogen ConcentratePhase 2 · Congenital AfibrinogenemiaClinicalTrials.gov · fetched Nov 12, 2026
- IGIV-CPhase 2 · Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- IGIV-CPhase 2 · Myasthenia Gravis, GeneralizedClinicalTrials.gov · fetched Nov 12, 2026
- Liquid Alpha1-Proteinase Inhibitor (Human)Phase 2 · Alpha1-Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- Liquid Alpha1-Proteinase Inhibitor (Human)Phase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- Plasma ExchangePhase 2 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Standard Medical TreatmentPhase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- Immune Globulin (Human)Anti-Hepatitis A Antibody Levels in Heathy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials24
- A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)PHASE3 · RECRUITING · started May 5, 2026ClinicalTrials.gov NCT07555483 · fetched Nov 12, 2026
- A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyPHASE3 · RECRUITING · started Apr 2, 2026ClinicalTrials.gov NCT07540221 · fetched Nov 12, 2026
- A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaPHASE3 · RECRUITING · started Dec 26, 2022ClinicalTrials.gov NCT05645107 · fetched Nov 12, 2026
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin DeficiencyPHASE1_PHASE2 · COMPLETED · started Dec 16, 2021ClinicalTrials.gov NCT04722887 · fetched Nov 12, 2026
- Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)PHASE2 · TERMINATED · started Jan 29, 2021ClinicalTrials.gov NCT04547140 · fetched Nov 12, 2026
- Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With CirrhosisPHASE1 · WITHDRAWN · started Jan 1, 2021ClinicalTrials.gov NCT04055389 · fetched Nov 12, 2026
- A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary ImmunodeficiencyPHASE4 · COMPLETED · started Nov 24, 2020ClinicalTrials.gov NCT04566692 · fetched Nov 12, 2026
- Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)PHASE2 · COMPLETED · started Sep 17, 2020ClinicalTrials.gov NCT04480424 · fetched Nov 12, 2026
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral ImmunodeficiencyPHASE3 · COMPLETED · started Sep 2, 2020ClinicalTrials.gov NCT04561115 · fetched Nov 12, 2026
- Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary ImmunodeficiencyPHASE3 · WITHDRAWN · started Dec 1, 2019ClinicalTrials.gov NCT03814798 · fetched Nov 12, 2026
- Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and AscitesPHASE3 · COMPLETED · started Jul 24, 2018ClinicalTrials.gov NCT03451292 · fetched Nov 12, 2026
- Alphanate in Immune Tolerance Induction TherapyPHASE2 · TERMINATED · started Jan 3, 2018ClinicalTrials.gov NCT03095287 · fetched Nov 12, 2026
- Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)PHASE4 · COMPLETED · started Oct 31, 2017ClinicalTrials.gov NCT03351933 · fetched Nov 12, 2026
- Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral SclerosisPHASE2 · COMPLETED · started Aug 29, 2016ClinicalTrials.gov NCT02872142 · fetched Nov 12, 2026
- Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital AfibrinogenemiaPHASE1_PHASE2 · COMPLETED · started Jul 22, 2016ClinicalTrials.gov NCT02281500 · fetched Nov 12, 2026
- Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin DeficiencyPHASE3 · ENROLLING_BY_INVITATION · started Jul 1, 2016ClinicalTrials.gov NCT02796937 · fetched Nov 12, 2026
- Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary ImmunodeficiencyPHASE3 · COMPLETED · started Jan 1, 2016ClinicalTrials.gov NCT02604810 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia GravisPHASE2 · COMPLETED · started Aug 1, 2015ClinicalTrials.gov NCT02473952 · fetched Nov 12, 2026
- Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia GravisPHASE2 · COMPLETED · started Jun 1, 2015ClinicalTrials.gov NCT02473965 · fetched Nov 12, 2026
- Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary BypassPHASE2 · COMPLETED · started Jun 26, 2014ClinicalTrials.gov NCT02037555 · fetched Nov 12, 2026
- Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)PHASE3 · COMPLETED · started May 28, 2014ClinicalTrials.gov NCT02104245 · fetched Nov 12, 2026
- Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)PHASE3 · COMPLETED · started Apr 1, 2014ClinicalTrials.gov NCT01983241 · fetched Nov 12, 2026
- Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)PHASE3 · COMPLETED · started Mar 31, 2014ClinicalTrials.gov NCT01515007 · fetched Nov 12, 2026
- Intravenous Gammaglobulin for Sickle Cell Pain CrisesPHASE1_PHASE2 · COMPLETED · started Nov 1, 2008ClinicalTrials.gov NCT01757418 · fetched Nov 12, 2026